Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Friedrichshall – page 6

851 clinical trials in Bad Friedrichshall, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Friedrichshall at a glance
851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

851 trials in Bad Friedrichshall

Open in trial search

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD8965
  • Sponsor:AstraZeneca AB

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Safety Study of CD19.CAR T Cells in Patients with Autoimmune‑Associated Severe Interstitial Lung Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:HD-CAR-1
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TRI-611
  • Sponsor:Triana Biomedicines Inc.

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Friedrichshall

What the registry says about research in the country

01 Cardiovascular Disease Research

Clinical trials focusing on atherosclerotic cardiovascular disease are evaluating innovative therapies to reduce major adverse cardiovascular events. These studies aim to improve outcomes for patients at high cardiovascular risk.

  • Coronary Heart Disease
  • Myocardial Infarction
  • Ischemic Stroke Prevention

Research emphasizes the development of new therapeutic approaches for arterial health management.

02 Heart Failure Studies

Groundbreaking research combines empagliflozin with novel compounds to address heart failure management. These trials specifically target patients with reduced left ventricular ejection fraction.

  • Combination Therapy Assessment
  • Cardiovascular Mortality Reduction
  • Hospital Admission Prevention

The studies aim to enhance current treatment protocols for heart failure patients.

03 Cardiac Rhythm Management

Important clinical research in atrial fibrillation and acute coronary syndrome is evaluating new anticoagulation strategies. These trials focus on preventing cardioembolic events and improving post-heart attack outcomes.

  • Stroke Prevention
  • Systemic Embolism Prevention
  • Post-Heart Attack Care

The research aims to establish more effective therapeutic options for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.